{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:24Z","timestamp":1767135024235,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010832","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T00:00:00Z","timestamp":1467417600000}}],"reference-count":95,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010832.pub2","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T07:59:14Z","timestamp":1467446354000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluphenazine (oral) versus atypical antipsychotics for schizophrenia"],"prefix":"10.1002","volume":"2016","author":[{"given":"James R","family":"Sampford","sequence":"first","affiliation":[{"name":"Bootham Park Hospital; Crisis and Access Service; York UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Sampson","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Institute of Mental Health University of Nottingham Innovation Park, Jubilee Campus Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao Guo","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Medical University Cancer Institute and Hospital; Interventional therapy department; Huan-Hu-Xi Road, Ti-Yuan-Bei,He Xi District Tianjin China 300060"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Systematic Review Solutions Ltd; 5-6 West Tashan Road Yan Tai Tianjin China 264000"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Xia","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health University of Nottingham Innovation Park, Triumph Road, Nottingham UK NG7 2TU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek A","family":"Furtado","sequence":"additional","affiliation":[{"name":"University of Warwick; Division of Mental Health and Wellbeing, Warwick Medical School; Gibbet Hill Road Coventry West Midlands UK CV4 7AL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,2]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010832.pub2-BIB0002|cit1","first-page":"593","article-title":"Efficacy of low doses of atypical neuroleptics (benzamides) in defect states","volume":"144","author":"Boyer","year":"1986","journal-title":"Annales Medico-Psychologiques"},{"issue":"4","key":"10.1002\/14651858.CD010832.pub2-BIB0001|cit2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1017\/S0767399X0000095X","article-title":"Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools","volume":"2","author":"Boyer","year":"1987","journal-title":"Psychiatrie and Psychobiologie"},{"issue":"3","key":"10.1002\/14651858.CD010832.pub2-BIB0003|cit3","first-page":"312","article-title":"A double blind, controlled, multicenter trial of low dose amisulpride (solian (R) 50) versus low dose fluphenazine in the treatment of negative symptoms in chronic schizophrenia","volume":"3","author":"Pichot","year":"1988","journal-title":"Annales de Psychiatrie"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0004|cit4","first-page":"125-38","article-title":"Controlled double-blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia","volume-title":"Amisulpride","author":"Pichot","year":"1989"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0006|cit5","unstructured":"Conley RR New antipsychotic strategies: quetiapine and risperidone vs. fluphenazine in treatment resistant schizophrenia Http:\/\/www.clinicaltrials.gov 2005"},{"issue":"4","key":"10.1002\/14651858.CD010832.pub2-BIB0005|cit6","first-page":"163","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"31","author":"Conley","year":"2005","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0007|cit7","unstructured":"Kelly D Conley RR Sexual side effects of quetiapine and risperidone compared with fluphenazine Psychoneuroendocrinology 1999"},{"issue":"3","key":"10.1002\/14651858.CD010832.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","article-title":"A randomised double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia","volume":"31","author":"Kelly","year":"2006","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine","volume":"66","author":"Kelly","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0010|cit10","unstructured":"Dossenbach M Friedel P Jakovljevic M Hotujac L Folnegovic V Uglesic B Olanzapine versus fluphenazine - six weeks treatment of acute schizophrenia 10th European Colleague of Neuropsychopharmacology Congress; 1997 September 13-17; Vienna 1997"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Dossenbach M Jakovljevic M Folnegovi V Uglesic B Dodig G Friedel P Olanzapine versus fluphenazine - six weeks of treatment of anxiety symptoms during acute schizophrenia Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria 1998 203","DOI":"10.1016\/S0920-9964(97)88822-6"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2003.10.010","article-title":"Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia","volume":"28","author":"Dossenbach","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0013|cit13","unstructured":"Jakovljevic M Dossenbach MR Friedel P Schausberger B Grundy SL Hotujac L Olanzapine versus fluphenazine in the acute (six week) treatment of schizophrenia Psychiatria Danubina 1999 3 11"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0014|cit14","unstructured":"Jakovljevic M Dossenbach MRK Olanzapine versus fluphenazine in the acute (six week) treatment of schizophrenia Psychiatria Danubina 1999 3 10"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pnpbp.2006.10.007","article-title":"The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study","volume":"31","author":"Jakovljevic","year":"2007","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD010832.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000119075","article-title":"Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine","volume":"29","author":"Saletu","year":"1994","journal-title":"Neuropsychobiology"},{"issue":"6","key":"10.1002\/14651858.CD010832.pub2-BIB0018|cit17","first-page":"593","article-title":"Efficacy of low doses of atypical neuroleptics (benzamides) in defect states","volume":"144","author":"Boyer","year":"1986","journal-title":"Annales Medico-Psychologiques"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000418016","article-title":"Treatment of positive and negative symptoms: pharmacologic approaches","volume":"24","author":"Boyer","year":"1990","journal-title":"Modern Problems of PharmacoPsychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0019|cit19","first-page":"83","article-title":"A controlled double-blind multi-centre trial of high dose amisulpride versus haloperidol in acute psychotic states","volume-title":"Amisulpride","author":"Pichot","year":"1989"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0020|cit20","unstructured":"Pichot P Boyer P A double blind, controlled, multicenter trial of amisulpride versus high dose haloperidol in acute psychotic disorders Annales de Psychiatrie 1988 326 32"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0024|cit21","first-page":"111","article-title":"Amisulpride in the treatment of negative schizophrenic symptoms: results of a double-blind controlled trial versus placebo","volume-title":"Amisulpride","author":"Boyer","year":"1989"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0021|cit22","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000418016","article-title":"Treatment of positive and negative symptoms: pharmacologic approaches","volume":"24","author":"Boyer","year":"1990","journal-title":"Modern Problems of PharmacoPsychiatry"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0022|cit23","first-page":"300","article-title":"A controlled study versus placebo with low dose of amisulpride in the treatment of the purely deficit schizophrenia","volume":"15","author":"Boyer","year":"1989","journal-title":"L'Encephale"},{"issue":"3","key":"10.1002\/14651858.CD010832.pub2-BIB0023|cit24","first-page":"321","article-title":"Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results","volume":"3","author":"Boyer","year":"1988","journal-title":"Annales de Psychiatrie"},{"issue":"5","key":"10.1002\/14651858.CD010832.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1017\/S0767399X00002467","article-title":"Improvement by amisulpride of the negative syndrome in non-psychotic subjects: a preliminary study","volume":"3","author":"Lecrubier","year":"1988","journal-title":"Psychiatrie and Psychobiologie"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0026|cit26","unstructured":"Boyer P Turjanski S Fleurot O Amisulpride in the treatment of acute schizophrenia: a double-blind comparison with haloperidol Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia 1996"},{"issue":"4","key":"10.1002\/14651858.CD010832.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s002130050361","article-title":"Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol","volume":"132","author":"M\u00f6ller","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0028|cit28","first-page":"199","article-title":"Treatment of schizophrenic patients with actue exacerbations: a double-blind comparison of amisulpride and haloperidol","volume":"30","author":"M\u00f6ller","year":"1997","journal-title":"PharmacoPsychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0029|cit29","unstructured":"M\u00f6ller HJ Boyer P Turjanski S Fleurot O Amisulpride in the treatment of subchronic or chronic schizophrenia with acute exacerbation: a double-blind comparison with haloperidol Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK 1996"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0030|cit30","doi-asserted-by":"crossref","unstructured":"Pickar D Owen RR Litman RE Konicki E Gutierrez R Rapaport MH Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine Archives of General Psychiatry 1992 345 53","DOI":"10.1001\/archpsyc.1992.01820050009001"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0031|cit31","unstructured":"Ravanic DB Djukic-Dejanovic SM Stojiljkovic M Jankovic S Paunovic VR Bankovic D Antipsychotic efficacy of clozapine vs fluphenazine in positive and negative schizophrenia syndrome Journal of Neural Transmission 1996 Xlvi"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0032|cit32","unstructured":"Djukic-Dejanovic SM Pantovic MM Alexopulos C Milovanovic DR Paunovic VR Ravanic DB Clozapine vs. classical antipsychotics in schizophrenia Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan 2002"},{"issue":"7066","key":"10.1002\/14651858.CD010832.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD010832.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","article-title":"Negative symptoms in schizophrenia: definition and reliability","volume":"39","author":"Andreasen","year":"1982","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010832.pub2-BIB0035|cit35","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD010832.pub2-BIB0037|cit37","first-page":"405","article-title":"The problem of therapeutic efficacy indices, 3: comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0038|cit38","unstructured":"Cost-Effectiveness Analysis Registry (CEA) https:\/\/research.tufts-nemc.org\/cear4\/ accessed 11\/09\/13"},{"issue":"4","key":"10.1002\/14651858.CD010832.pub2-BIB0039|cit39","first-page":"167","article-title":"Fluphenazine: a preliminary study","volume":"20","author":"Darling","year":"1959","journal-title":"Disease of the Nervous System"},{"issue":"JULY","key":"10.1002\/14651858.CD010832.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1192\/bjp.bp.106.028654","article-title":"Cost-effectiveness of first- vs. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy","volume":"191","author":"Davies","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0041|cit41","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/BF00176852","article-title":"Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine","volume":"94","author":"Dencker","year":"1988","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1002\/14651858.CD010832.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"3 August","key":"10.1002\/14651858.CD010832.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD010832.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/BF00422403","article-title":"Fluphenazine pharmacokinetics and therapeutic response","volume":"73","author":"Dysken","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0049|cit49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000059.pub2","article-title":"Clozapine versus typical neuroleptic medication for schizophrenia","author":"Essali","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2 Spring","key":"10.1002\/14651858.CD010832.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria","volume":"21","author":"Evers","year":"2005","journal-title":"International Journal of Technology Assessment in Health Care"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0051|cit51","first-page":"222","article-title":"The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacological Bulletin"},{"issue":"7","key":"10.1002\/14651858.CD010832.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0053|cit53","first-page":"223","article-title":"Scale formation in the AMDP-system","volume":"233","author":"Gebhardt","year":"1983","journal-title":"Archives of Psychiatry and Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90196-U","article-title":"Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia","volume":"41","author":"Grace","year":"1991","journal-title":"Neuroscience"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0056|cit56","first-page":"124","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0057|cit57","unstructured":"Guy E Abnormal Involuntary Movement Scale Rockville, MD, National Institute of Mental Health, U.S. Department of Health and Human Services: ECDEU Assessment Manual for Psychopharmacology 1976"},{"issue":"5","key":"10.1002\/14651858.CD010832.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"e001810","DOI":"10.1136\/bmjopen-2012-001810","article-title":"Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010","volume":"2","author":"Healy","year":"2012","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0059|cit59","unstructured":"Health Economic Evaluation Database (HEED) Online ISBN: 9780470510933 10.1002\/9780470510933"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0060|cit60","unstructured":"Hospital Episode Statistics, Admitted Patient Care - England 2011-12: Main Specialties (.xls) http:\/\/www.hscic.gov.uk\/searchcatalogue?productid=9161&q=title%3a%22hospital+episode+statistics%22&sort=Relevance&size=10&page=1#top (accessed May 2013)"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0062|cit62","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychological Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia - cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD010832.pub2-BIB0066|cit66","first-page":"30","article-title":"Depot neuroleptics: a comparison review of standard, intermediate and low-dose regimens","volume":"47","author":"Kane","year":"1986","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0067|cit67","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1192\/bjp.bp.110.083766","article-title":"The rise and fall of the atypical antipsychotics","volume":"199","author":"Kendall","year":"2011","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD010832.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"9657","key":"10.1002\/14651858.CD010832.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010832.pub2-BIB0074|cit74","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000307.pub2","article-title":"Fluphenazine decanoate (depot) and enanthate for schizophrenia","author":"Maayan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","article-title":"The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders","volume":"14","author":"Maier","year":"1988","journal-title":"Journal of Affective Disorders"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0076|cit76","first-page":"23-41","article-title":"Cost of schizophrenia in England","volume":"10","author":"Mangalore","year":"2007","journal-title":"Journal of Mental Health Policy and Economics"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"issue":"7","key":"10.1002\/14651858.CD010832.pub2-BIB0079|cit79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006352.pub2","article-title":"Fluphenazine (oral) versus placebo for schizophrenia","author":"Matar","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiological Review"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1192\/bjp.109.460.428","article-title":"A trial of fluphenazine in schizophrenia","volume":"109","author":"Millar","year":"1963","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0082|cit82","unstructured":"National Institute for Health and Clinical Excellence The Epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care (Pharmacological Update of Clinical Guideline 20) NCGC National Clinical Guideline Centre 2012 1 636"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00434408","article-title":"The Leeds sleep evaluation questionnaire in psychopharmacological investigations - a review","volume":"71","author":"Parrott","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0085|cit85","unstructured":"Compiled by Lesley Curtis Unit costs of health and social care 2012 http:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/2012\/ (accessed May 2013) 2012 47"},{"issue":"5","key":"10.1002\/14651858.CD010832.pub2-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0087|cit87","doi-asserted-by":"crossref","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions In: Higgins JPT, Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184.ch12"},{"issue":"1","key":"10.1002\/14651858.CD010832.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/070674370204700106","article-title":"Atypical antipsychotics: mechanism of action","volume":"47","author":"Seeman","year":"2002","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandanavica"},{"issue":"8","key":"10.1002\/14651858.CD010832.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009230.pub2","article-title":"Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia","author":"Tardy","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010832.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"6","key":"10.1002\/14651858.CD010832.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/schbul\/sbn117","article-title":"Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions","volume":"34","author":"Os","year":"2008","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0093|cit93","unstructured":"Essential Medicines: WHO model list http:\/\/whqlibdoc.who.int\/hq\/2005\/a87017_eng.pdf March 2005"},{"key":"10.1002\/14651858.CD010832.pub2-BIB0094|cit94","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-349-18800-0_1","article-title":"Health economics: the cheerful face of dismal science?","volume-title":"Health and Economics","author":"Williams","year":"1987"},{"issue":"7","key":"10.1002\/14651858.CD010832.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010832.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:41:56Z","timestamp":1748979716000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010832.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,7,2]]},"references-count":95,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010832.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,2]]}}}